Here are the top ten regulatory news stories to follow this week: Arbor Pharmaceuticals and Debiopharm International announced that the FDA has approved Triptodur for the treatment of pediatric patients 2 years and older with central precocious puberty. Full Story Here Bristol-Myers Squibb’s ORENCIA (abatacept) received FDA approval for treatment of active Psoriatic Arthritis (PsA) in adults. Orencia has been previously[…]